Psilocybin For IBS Gets FDA Nod To Begin Clinical Trials At Mass. General Hospital
Portfolio Pulse from Lara Goldstein
Tryp Therapeutics' (OTCQB:TRYPF) Investigational New Drug (IND) application has been approved by the FDA, allowing the company to begin Phase 2a clinical trials at Massachusetts General Hospital on the effects of psilocybin-assisted psychotherapy for adults with Irritable Bowel Syndrome (IBS). The company's lead psilocin compound TRP-8803 is currently being assessed in a Phase 2a trial for the treatment of binge eating disorder. Its synthetic oral psilocybin, TRP-8802, will be studied in a Phase 2a trial for the treatment of fibromyalgia and IBS.
July 13, 2023 | 7:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tryp Therapeutics' FDA approval to begin Phase 2a clinical trials for psilocybin-assisted psychotherapy for IBS could potentially boost the company's stock in the short term.
The FDA approval for Tryp Therapeutics to begin Phase 2a clinical trials for its psilocybin-assisted psychotherapy for IBS represents a significant milestone for the company. This could potentially lead to increased investor confidence and a boost in the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100